Zobrazeno 1 - 10
of 411
pro vyhledávání: '"Lars, Iversen"'
Autor:
Maria Danielsen, Thomas Emmanuel, Morten Muhlig Nielsen, Lise Maria Lindahl, Maria Gluud, Niels Ødum, Line Raaby, Torben Steiniche, Lars Iversen, Rikke Bech, Terkild Brink Buus, Claus Johansen
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionThe majority of patients with mycosis fungoides (MF) have an indolent disease course, but a substantial fraction (20-30%) of patients progress to advanced stages – usually with a grave prognosis. Early differentiation between indolent a
Externí odkaz:
https://doaj.org/article/032ca7a08f2441cebfb7829eb806389e
Autor:
Sissel Brandt Toft Sørensen, Prethibha George, Oladayo Jagun, Robert Wolk, Lynne Napatalung, Samuel H. Zwillich, Lars Iversen, Vera Ehrenstein
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 4, Pp 993-1006 (2024)
Abstract Introduction Alopecia areata (AA) is an autoimmune skin disease presenting as nonscarring hair loss. Information on the epidemiology of AA, especially the occurrence of AA and its subtypes within the general population, is scarce. The study
Externí odkaz:
https://doaj.org/article/c57380e937764ae587523e55fe6732cd
Autor:
Sailan Wang, Pernilla Nikamo, Leena Laasonen, Bjorn Gudbjornsson, Leif Ejstrup, Lars Iversen, Ulla Lindqvist, Jessica J Alm, Jesper Eisfeldt, Xiaowei Zheng, Sergiu-Bogdan Catrina, Fulya Taylan, Raquel Vaz, Mona Ståhle, Isabel Tapia-Paez
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 3, Pp 596-615 (2024)
Abstract Psoriatic arthritis mutilans (PAM) is the rarest and most severe form of psoriatic arthritis, characterized by erosions of the small joints and osteolysis leading to joint disruption. Despite its severity, the underlying mechanisms are unkno
Externí odkaz:
https://doaj.org/article/d7a494fdd8c144ae87005d0481ad98df
Autor:
Tiago Torres, Jordi Galván, Nigel Crutchley, Morten Praestegaard, Lars Iversen, Paolo Gisondi, José Manuel Carrascosa, Bruno Halioua, Anthony Bewley, Andreas Pinter
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 10, Pp 2153-2169 (2023)
Abstract Topical treatment plays a crucial role in psoriasis management, with non-adherence being a major barrier to treatment success. The fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) represents the first-line ch
Externí odkaz:
https://doaj.org/article/b05d2962ef644edebef73ab4bc98c535
Autor:
Linda Stein Gold, Andreas Pinter, April Armstrong, Matthias Augustin, Petr Arenberger, Neil Bhatia, Morten Praestegaard, Lars Iversen, Adam Reich
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 9, Pp 2031-2044 (2023)
Abstract Introduction Psoriasis ranges from mild to severe with the majority of patients having mild disease. Mild to moderate disease is often treated with topical therapies while photo-, oral, and biologic therapies are generally reserved for moder
Externí odkaz:
https://doaj.org/article/3bfde76e354a4313a41209279070597e
Autor:
Flora Nicol Balieva, Louise Catton, Birgitta W. Claréus, Kjersti Danielsen, Frederik Fierens, Lars Iversen, Leena Koulu, Amra Osmanecevic, Rafael Pasternack, Lone Skov
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 8, Pp 1873-1887 (2023)
Abstract Introduction The purpose of this study is to explore treatment preferences and identify patient characteristics in young bio-naive adults with moderate to severe psoriasis in the Nordic countries (Norway, Finland, Sweden, and Denmark). Metho
Externí odkaz:
https://doaj.org/article/7769d96ecdfb461ca75da58bc03abef7
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
BackgroundHeat shock protein 90 (HSP90) is an important chaperone supporting the function of many proinflammatory client proteins. Recent studies indicate HSP90 inhibition may be a novel mechanism of action for inflammatory skin diseases; however, th
Externí odkaz:
https://doaj.org/article/f467e1c9a7b047479ba2c01ba6bc2563
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Background Clinical trials have shown promising results for interleukin-23 inhibitors in the treatment of psoriasis. The drugs have been used in clinical practice since 2017. Objective To investigate the drug survival and effectiveness of interleukin
Externí odkaz:
https://doaj.org/article/10a5648cc6e64393995bdde377b92ddc
Publikováno v:
Drugs in R&D, Vol 23, Iss 2, Pp 155-163 (2023)
Abstract Background Clinical trials have established the efficacy of brodalumab in treatment of psoriasis and psoriatic arthritis. Real-world evidence is needed to fully evaluate the drug. Objective Here we investigate drug survival and clinical effe
Externí odkaz:
https://doaj.org/article/3bc3416d21ce48349d89db6dc952b3b1
Autor:
Nuria García, Pere Guiró, Jordi Galván, Nigel Crutchley, Morten Praestegaard, Lars Iversen, Tiago Torres
Publikováno v:
Drugs in Context, Vol 12, Pp 1-8 (2023)
Background: In psoriasis, poor treatment adherence is frequently related to low efficacy and limited cosmetic acceptability from the patients’ perspective. This study aimed to characterize the sensorial attributes of a calcipotriol (CAL) and betame
Externí odkaz:
https://doaj.org/article/a14a2e8ac2af477ca6d0b821b7071077